First case series on the use of imiquimod for morphoea.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16181467.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta. Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea. Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months. The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. This is the first case series describing the successful application of imiquimod in the management of morphoea.
Medical subject headings
- Aminoquinolines
- Interferon Inducers
- Scleroderma, Localized